Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
Healthcare
$3.83 -3.37%
-$0.34 today
- Market cap
- $189.33M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
52W Low $1.47High $14.53
Volume 0.77M
Average 0.48M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$90.61M
FY 2025 · Annual
Net Income
-$83.86M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2M | 4.93M | 33.49M | 251K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.6M |
| Gross Profit | 2M | 4.93M | 33.49M | 251K | (2.6M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Research & Development | 42.41M | 43.98M | 50.25M | 50.33M | 69.54M |
| Selling, General & Admin | 12.86M | 20.78M | 13.91M | 17.21M | 20.27M |
| Operating Expenses | 55.27M | 64.76M | 64.16M | 67.53M | 88.01M |
| Depreciation & Amortization | 248K | 1.16M | 2.27M | 2.43M | 2.6M |
| EBITDA | (71.58M) | (57.18M) | (25.36M) | (56.06M) | (81.27M) |
| EBITDA Margin | -3575.3% | -1159.5% | -75.7% | -22335.5% | — |
| Operating Income | (53.27M) | (59.83M) | (30.67M) | (67.28M) | (90.61M) |
| Operating Margin | -2660.9% | -1213.3% | -91.6% | -26805.6% | — |
| Interest Income | 0 | 1.29M | 2.54M | 5.35M | 5.96M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (18.55M) | 1.49M | 3.05M | 8.79M | 6.75M |
| Income Before Tax | (71.83M) | (58.34M) | (27.62M) | (58.49M) | (83.87M) |
| Pre-Tax Margin | -3587.7% | -1183.0% | -82.5% | -23304.0% | — |
| Income Tax Expense | 0 | 53K | 72K | 0 | 0 |
| Net Income | (71.83M) | (58.39M) | (27.7M) | (58.49M) | (83.87M) |
| Net Margin | -3587.7% | -1184.1% | -82.7% | -23304.0% | — |
| EPS (Basic) | (4.08) | (3.32) | (1.19) | (5.20) | (3.43) |
| EPS (Diluted) | (4.08) | (3.32) | (1.19) | (5.20) | (3.43) |
| 17.58M | 17.58M | 23.28M | 24.36M | 24.44M | |
| 17.58M | 17.58M | 23.28M | 24.36M | 24.44M |
ARTV Earnings Waterfall · TTM
NASDAQ:ARTV · Revenue to Net Income
Key Ratios
EPS$-3.55
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.1
P/S Ratio0.0
Analysis
$0 of revenue converted into -$87.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.55, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K/A | 8-K/A filing | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
How much revenue does ARTV generate?
Artiva Biotherapeutics, Inc. (ARTV) reported $0.00 of revenue in fiscal 2025.
Is ARTV profitable?
Artiva Biotherapeutics, Inc. (ARTV) reported -$83.86M of net income.
Continue the stock analysis
Jump to another research area for this company.